For Patients With Ischemic Stroke, Clinically Study the Effectiveness and Safety of Butylphthalide.

Launched by QIANFOSHAN HOSPITAL · Oct 2, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a medication called butylphthalide for patients who have experienced an ischemic stroke, which occurs when a blood vessel in the brain is blocked. The researchers aim to enroll 300 patients who are at least 18 years old and have had an acute ischemic stroke within the last 48 hours. Before participating, patients will be screened to ensure they don’t have any bleeding in the brain or other serious health issues that could complicate their treatment.

Participants in this trial will receive butylphthalide and will be closely monitored to assess how well the medication works and if there are any side effects. The study will also look specifically at older patients to understand how the drug behaves in their bodies. This trial is currently recruiting participants, so if you or someone you know has recently had an ischemic stroke and meets the eligibility criteria, this could be an opportunity to help advance treatment options while receiving care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Female or male aged ≥ 18 years.
• • 2. Acute ischemic stroke within 48 hours of onset
• • 3. Examination to exclude intracranial hemorrhage
• • 4. Provision of informed consent.
• Exclusion Criteria:
• • 1.Head CT or MRI suggests the presence of intracranial hemorrhagic disease
• • 2.Patients with cerebral embolism or suspected cerebral embolism with severe atrioventricular block disease, atrial fibrillation, myocardial infarction, heart valve disease, infective endocarditis, heart rate less than 50 beats per minute
• • 3.Abnormal liver function (transaminase ALT or AST exceeding the upper limit of normal), abnormal renal function (creatinine exceeding the upper limit of normal), or suffering from other serious systemic diseases, etc
• • 4.Allergy to Butylphthalide